We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00433927
Recruitment Status : Unknown
Verified March 2014 by PD Dr. med. Volker Heinemann, Ludwig-Maximilians - University of Munich.
Recruitment status was:  Active, not recruiting
First Posted : February 12, 2007
Last Update Posted : March 14, 2014
Merck KGaA
Information provided by (Responsible Party):
PD Dr. med. Volker Heinemann, Ludwig-Maximilians - University of Munich

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : April 2014
  Estimated Study Completion Date : December 2016
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):